Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Houston, Texas 77030


RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Treating a person's or donor's a cytotoxic T lymphocytes in the laboratory and reinfusing them may cause a stronger immune response to kill Epstein-Barr virus-associated cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of autologous or donor cytotoxic T-lymphocytes in treating patients with relapsed Epstein-Barr virus-associated Hodgkin's lymphoma or non-Hodgkin's lymphoma.

Study summary:

OBJECTIVES: - Determine the safety of autologous or allogeneic LMP2A-specific cytotoxic T-lymphocytes in patients with relapsed Epstein-Barr virus-positive Hodgkin's or non-Hodgkin's lymphoma. - Determine the survival and immune function of patients treated with this regimen. - Determine the antiviral and antitumor effects of this regimen in these patients. - Obtain preliminary information on the safety of and response to an extended dosage of this regimen in these patients. OUTLINE: Peripheral blood is collected from the patient or a donor and allogeneic or autologous dendritic cells (DC) are generated over 7 days using sargramostim (GM-CSF) and interleukin-4 (IL-4). DC are transduced with recombinant AdLMP2A and matured with GM-CSF, TNFa, PGE-1, and IL-4 over 2 days to stimulate cytotoxic T-lymphocytes (CTL). Patients receive LMP2A-specific CTL IV over 1-10 minutes on days 0 and 14. Cohorts of 3-6 patients receive escalating doses of LMP2A-specific CTL. Patients are evaluated at 8 weeks. Patients with stable disease or a partial response may receive 6 additional doses of LMP2A-specific CTL IV over 1-10 minutes once monthly. PROJECTED ACCRUAL: A total of 18 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Diagnosis of Epstein-Barr virus-positive Hodgkin's or non-Hodgkin's lymphoma - Any histological subtype - Meets criteria for 1 of the following: - Second or subsequent relapse (or first relapse or with active disease if immunosuppressive chemotherapy is contraindicated (e.g., patients who develop Hodgkin's lymphoma after a prior solid organ transplant, who have lymphoma as a second malignancy, or who have relapsed multiple times AND at high risk of relapse) (group A) - In remission OR with minimal residual disease after autologous stem cell transplantation for Hodgkin's or non-Hodgkin's lymphoma or lymphoepithelioma (group B) - In remission OR with detectable disease after allogeneic stem cell transplantation (group C) PATIENT CHARACTERISTICS: Age - Any age Performance status - Karnofsky 50-100% Life expectancy - At least 6 weeks Hematopoietic - Hemoglobin greater than 8.0 g/dL - More than 50% donor chimerism in either peripheral blood or bone marrow after allogeneic stem cell transplantation - No evidence of graft-vs-host disease > grade II Hepatic - Bilirubin less than 3 times normal - AST less than 5 times normal Renal - Creatinine less than 2 times normal Other - Not pregnant - Fertile patients must use effective contraception - No concurrent severe infection - HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy - See Disease Characteristics Chemotherapy - Not specified Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified Other - More than 1 month since prior investigational therapy



Primary Contact:

Study Chair
Helen E. Heslop, MD
Baylor College of Medicine

Backup Contact:


Location Contact:

Houston, Texas 77030
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.